Pharmacyclics Inc $94.48

up +0.87


24/4/2014 05:20 PM  |  NASDAQ : PCYC  
Industries : Drugs / Drug Manufacturers - Other
Get Trend Analysis Icon Get PCYC Trend Analysis - it has underperformed the S&P 500 by 5%

Partner Headlines

  1. Mid-Afternoon Market Update: Markets Continue to Take a Beating as Rite ...

    Benzinga
  2. Mid-Day Market Update: Rite Aid Shares Gain On Upbeat Earnings; Imperva ...

    Benzinga
  3. Pharmacyclics Files Supplemental New Drug Application for IMBRUVICA with ...

    Benzinga
  4. Morgan Stanley's Top Biotech Pick is Biogen

    Benzinga
  5. Morgan Stanley Starts Pharmacyclics With Equal-Weight; $120 PT -Reuters

    Benzinga
  6. Celegene, Pharmacyclics Lead Biotech Short Interest Trend (CELG, MDVN, ...

    Benzinga
  7. Pharmacyclics target raised

    IBD
  8. Pharmacyclics Drug Imbruvica Beats Rivals: Nomura

    IBD
  9. Kiplinger's Tom Petruno Breaks Down The Best Bull Market Stocks

    Benzinga
  10. WuXi Pharma Q4 Earnings Top, But Q1 Guidance Misses

    IBD
  11. Weekly Insider Sells Highlight: BX, PCYC, MAS, ITMN

    GuruFocus
  12. Pharmacyclics Hits High As Imbruvica Launches Big

    IBD
  13. FDA Approvals And Changes For The Week Ending February 14, 2014

    Benzinga
  14. BioMarin Bucks Biotech Short Interest Trend (BIIB, BMRN, MDVN)

    Benzinga
  15. Pharmacyclics up on FDA OK

    IBD
  16. Pharmacyclics' Imbruvica Wins Second Cancer Approval

    IBD
  17. Pharmacyclics: Facts Behind $10B Market Cap

    YCharts
  18. $10B Market By 2022: Pharmacyclic’s Piece Of It

    YCharts
  19. ETF Outlook for Wednesday, January 8, 2014 (ROBO, PBE, SMH, EUFN)

    Benzinga
  20. Pharmacyclics, Valeant, Celgene Up On Bullish News

    IBD
  21. Biotechs Jump On Drug News

    IBD
  22. PharmacyclicsDrug Trial To End Early On Strong Data

    IBD
  23. The Top Five Drug Launches Of 2013

    IBD
  24. Rising Short Interest In Pharmacyclics, Other Biotechs (AMGN, GILD, PCYC)

    Benzinga
  25. Qihoo, Noah Lead IBD 50's Top 5 Young Chinese Stocks

    IBD
  26. Pharmacyclics Announces Ibrutinib Frontline Chronic Lymphocytic Leukemia ...

    Benzinga
  27. Celgene, Infinity Rise On Blood Cancer Drug Data

    IBD
  28. 2 Top Biotechs Presenting Data At Hematology Event

    IBD
  29. 4 Potential Blockbuster Drugs Awaiting Launch

    IBD
  30. SouFun, Zeltiq Lead IBD's Top 5 With Bolting RS Lines

    IBD
  31. UPDATE: Piper Jaffray Initiates Coverage on Pharmacyclics as 2014 Biotech ...

    Benzinga
  32. Wedbush Reiterates on Pharmacyclics as IMBRUVICA Approved for Mantle Cell ...

    Benzinga
  33. Market Wrap For November 13: Markets Await Janet Yellen's Big Day Thursday

    Benzinga
  34. Pharmacyclics Drug Wins One Approval, Awaits Another

    IBD
  35. The U.S. Food and Drug Adminstration Approves Pharmacyclis Product For ...

    Benzinga
  36. Pharmacyclics, J&J's Janssen Now Confirming FDA Approval of IMBRUVICA

    Benzinga
  37. Gilead Sciences Leads In Rising Short Interest Among Biotechs

    Benzinga
  38. Short Sellers Retreat From Biogen Idec, Move On Pharmacyclics (BIIB, BMRN, ...

    Benzinga
  39. Pharmacyclics' Ibrutinib Could Crown Turnaround Story

    IBD
  40. J&J Reporting Q3 Earnings As Sentiment Edges Up

    IBD
  41. Short Sellers Move On Amgen, Vertex (AMGN, PCYC, VRTX)

    Benzinga
  42. Gilead Stock Jumps On Leukemia Drug News

    IBD
  43. Pharmacyclics hits new high

    IBD
  44. Pharmacyclics Hits New High As Bulls Launch Coverage

    IBD
  45. UPDATE: J.P. Morgan Initiates Coverage on Pharmacyclics on Ibrutinib Potential

    Benzinga
  46. Stocks Hitting 52-Week Highs

    Benzinga
  47. Benzinga's Top Initiations

    Benzinga
  48. BioMarin, Celgene Lead Trend in Biotech Short Interest (BRMN, CELG, REGN)

    Benzinga
  49. UPDATE: William Blair Initiates Coverage on Pharmacyclics on Good Market ...

    Benzinga
  50. Alexion, Pharmacyclics Buck Trend in Biotech Short Interest (ALXN, CELG, ...

    Benzinga
Trading Center